Italia markets close in 2 hours 44 minutes

GSK plc (GSK.L)

LSE - LSE Prezzo differito. Valuta in GBp (0.01 GBP).
Aggiungi a watchlist
1.419,60+4,20 (+0,30%)
Al 01:31PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente1.415,40
Aperto1.418,40
Denaro1.418,00 x 0
Lettera1.418,80 x 0
Min-Max giorno1.401,20 - 1.422,00
Intervallo di 52 settimane1.280,92 - 2.746,59
Volume1.159.670
Media Volume9.554.287
Capitalizzazione57,741B
Beta (5 anni mensile)0,32
Rapporto PE (ttm)13,02
EPS (ttm)1,09
Prossima data utili01 feb 2023
Rendimento e dividendo (forward)0,76 (5,47%)
Data ex dividendo17 nov 2022
Stima target 1AN/D
  • GlobeNewswire

    Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

    Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royaltiesCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare

  • GlobeNewswire

    GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

    The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agree

  • GlobeNewswire

    SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

    - SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat Commercially Available in Markets Where a Combination with Blenrep is Approved - - SpringWorks to Continue Retaining Full Global Commercial Rights to Nirogacestat - STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a cl